The conference was organized under the aegis of the pharmaceutical company Roche Georgia and is connected to the introduction of the innovative drug Ocrevus (Ocrelizumab) onto the Georgian pharmaceutical market.
Professor Ludwig Kapo, Head of the Neurology Department of Basel University Clinic, Head of Research Clinic of Clinical Neuroimhunology and Neuropathology, Doctor of Medicine, was invited from Switzerland to participate in the event as Honorary Rapporteur.
The goal of the Scientific Conference is to recommend Ocrevus for multiple sclerosis treatment, as a “modern medicine achievement for Georgian patients.”
Ocrevus is one of the first and only permitted therapies in the world used for recurrence and personally progressive sclerosis. The effectiveness and safety of Ocrevus was confirmed by large-scale clinical trials. Ocrevus is said to significantly suppress the disease activity and the risk of developing disability.
“Ocrevus Registration is an important event in Georgia for patients with multiple sclerosis,” explains Nino Ghugava, Medical Director of Roche Georgia.
According to Mrs. Chugava, patients with multiple sclerosis, despite treatment with existing therapy, often have a higher incidence of disease and require modification of treatment.
“Ocrevus is a new choice for them. And patients with initially progressive sclerosis, which has a faster progression of disease and disability, will have the opportunity to be treated with high efficacy. Ocrevus is an impressive novelty in both forms of multiple sclerosis treatment,” said Mrs. Chugava
Multiple sclerosis is a chronic, progressive neurological disease and 2.3 million people worldwide are sufferers. The first symptoms primarily occur between 20 and 40 years, and that is why multiple sclerosis is the main cause of non-traumatic disability in younger patients.